Merck & Co

Merck & Co . And Japan Tobacco Inc. today announced a worldwide licensing agreement to develop and marketing JTT-305, an orally osteoanabolic agent for the treatment of osteoporosis, a disease that causes bone density and strength and reduced to an increased risk of bone fractures.

Risks, uncertainties and other factors that could cause which could include materially from those which may carry in the forward – looking statements, without limitation:.

see more here

* Who is with a risk of sleep apnea? The National Heart Lung and Blood Institute, NIH, retrieve January 2008 from:** Continuous Positive Airway Pressure Therapy Discounted right ventricular volume in patients with OSA: One Cardiovascular Magnetic Resonance Study, Journal of Clinical Sleep Medicine, adopted on 18 November 2008. 3.2 times A Health Crisis: A window of opportunity Key change in lifestyle.

click to read more